Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Advances in Rheumatology

Edgard Torres dos Reis Neto¹  Marcelo de Medeiros Pinheiro¹  Emília Inoue Sato¹  Licia Maria Henrique da Mota²  Ana Paula Monteiro Gomides Reis²  Gecilmara Cristina Salviato Pileggi³  José Roberto Provenza⁴  Adriana Maria Kakehasi⁵  Gilda Aparecida Ferreira⁵  Cláudia Diniz Lopes Marques⁶  Eduardo dos Santos Paiva⁷  Ricardo Machado Xavier⁸ 

[1] Disciplina de Reumatologia, Escola Paulista de Medicina, Universidade Federal de São Paulo;Hospital Universitário - UnB/EBSERH;Instituto de Ensino e Pesquisa (IEP), Hospital Amor;Pontifícia Universidade Católica de Campinas;Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal de Minas Gerais;Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal de Pernambuco;Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal do Paraná;Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre da Universidade Federal do Rio Grande do Sul;

关键词: Hydroxychloroquine;    Chloroquine;    Antimalarials;    Chronic immune-mediated inflammatory rheumatic diseases;   

DOI  :  10.1186/s42358-020-00134-8

来源: DOAJ

【 摘 要 】

Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.

【 授权许可】

Unknown